Success Metrics

Completion Rate
0%(0/2)
Active Trials
5(33%)
Terminated
2(13%)

Phase Distribution

Ph phase_4
1
7%
Ph phase_1
4
27%
Ph phase_3
5
33%
Ph phase_2
4
27%

Phase Distribution

4

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
5(35.7%)
Phase 4Post-market surveillance
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

5

trials recruiting

Total Trials

15

all time

Status Distribution
Active(5)
Terminated(2)
Other(8)

Detailed Status

unknown8
Recruiting4
Terminated2
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
15
Active
5
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 14 (28.6%)
Phase 24 (28.6%)
Phase 35 (35.7%)
Phase 41 (7.1%)

Trials by Status

recruiting427%
terminated213%
unknown853%
active_not_recruiting17%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT04854668Phase 3

A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active Not Recruiting
NCT05481645Phase 2

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Terminated
NCT06379087Phase 2

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Recruiting
NCT05193604Phase 1

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Terminated
NCT05494060Phase 2

XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma

Recruiting
NCT05994365

Study of Anlotinib Hydrochloride Capsules in the Treatment of Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma

Recruiting
NCT05830500Phase 4

Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma

Recruiting
NCT05718167Phase 3

TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.

Unknown
NCT05559242Phase 1

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Unknown
NCT05549973Phase 1

Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma

Unknown
NCT05121350Phase 3

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Unknown
NCT05198531Phase 1

To Evaluate the Safety and Efficacy of TQB2858 Injection to the Subjects With Recurrent/Metastatic Nasopharyngeal Cancer

Unknown
NCT05068206Phase 2

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unknown
NCT04439890Phase 3

A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer

Unknown
NCT04385550Phase 3

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Unknown

All 15 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
15